JIAMING ZHANG

Dr. JIAMING ZHANG

Harvard School of Dental Medicine
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2022 in Ageing Research Reviews
Verified
Journal Article
Closed access
JCJiarui Cui
Jiarui Cui
YSYo Shibata
Yo Shibata
TZTianmin Zhu
Tianmin Zhu
JZJun Zhou
Jun Zhou
JIAMING ZHANGJIAMING ZHANG
JIAMING ZHANG

21 August 2023 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
JWJunlai Wan
Junlai Wan
ZHZhiyi He
Zhiyi He
RPRenpeng Peng
Renpeng Peng
XWXiaopei Wu
Xiaopei Wu
ZZZiqing Zhu
Ziqing Zhu
PCPeng Cheng
Peng Cheng
Osteoarthritis (OA) is a common degenerative joint disease urgently needing effective treatments. Bone marrow mesenchymal stromal cell-derived exosomes (Exo) are considered good drug carriers whereas they have limitations such as fast clearance and low retention. This study aimed to overcome the limitations of Exo in drug delivery using multiple strategies. Novel photocrosslinking spherical gelatin methacryloyl hydrogel (GelMA)-encapsulated cartilage affinity WYRGRL (W) peptide-modified engineered Exo were developed for OA treatment and the performance of the engineered Exo (W-Exo@GelMA) loaded with a small inhibitor LRRK2-IN-1 (W-Exo-L@GelMA) was investigated in vitro and in vivo. The W-Exo-L@GelMA showed an effective targeting effect on chondrocytes and a pronounced action on suppressing catabolism and promoting anabolism in vitro. Moreover, W-Exo-L@GelMA remarkably inhibited OA-related inflammation and immune gene expression, rescuing the IL-1β-induced transcriptomic responses. With enhanced retention in the joint, W-Exo-L@GelMA demonstrated superior anti-OA activity and cartilage repair ability in the OA murine model. The therapeutic effect was validated in the cultured human OA cartilage. In conclusion, photocrosslinking spherical hydrogel-encapsulated targeting peptide-modified engineered Exo exhibit notable potential in OA therapy. Engineering Exo by a series of strategies enhanced the targeting ability and retention and cartilage-targeting and Exo-mediated drug delivery may offer a novel strategy for OA treatment.Clinical trial registration: Not applciable. Graphical Abstract

1 January 2019 in Pharmacological Research
Verified
Journal Article
Closed access
XYXudong Yao
Xudong Yao
JIAMING ZHANGJIAMING ZHANG
JIAMING ZHANG
XJXingzhi Jing
Xingzhi Jing
YYYaping Ye
Yaping Ye
JGJiachao Guo
Jiachao Guo
FGFengjing Guo
Fengjing Guo

27 January 2021 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
XHxiaoxia hao
xiaoxia hao
XSXingru Shang
Xingru Shang
JLJiawei Liu
Jiawei Liu
CCChiRuimin Chi
ChiRuimin Chi
JIAMING ZHANGJIAMING ZHANG
JIAMING ZHANG
XTXu Tao
Xu Tao
Osteoarthritis (OA) is one of the most frequent musculoskeletal diseases characterized by degeneration of articular cartilage, subchondral bone remodeling, and synovial membrane inflammation, which is a leading cause of global disability, morbidity, and decreased quality of life. Interpreting the potential mechanisms of OA pathogenesis is essential for developing novel prevention and disease-modifying therapeutic interventions. Gut microbiota is responsible for a series of metabolic, immunological, and structural and neurological functions, potentially elucidating the heterogeneity of OA phenotypes and individual features. In this narrative review, we summarized research evidence supporting the hypothesis of a “gut-joint axis” and the interaction between gut microbiota and the OA-relevant factors, including age, gender, genetics, metabolism, central nervous system, and joint injury, elucidating the underlying mechanisms of this intricate interaction. In the context, we also speculated the promising manipulation of gut microbiota in OA management, such as exercise and fecal microbiota transplantation (FMT), highlighting the clinical values of gut microbiota. Additionally, future research directions, such as more convincing studies by the interventions of gut microbiota, the gene regulation of host contributing to or attributed to the specific phenotypes of gut microbiota related to OA, and the relevance of distinct cell subgroups to gut microbiota, are expected. Moreover, gut microbiota is also the potential biomarker related to inflammation and gut dysbiosis that is able to predict OA progression and monitor the efficacy of therapeutic intervention.

Verified
Journal Article
Open access
PDF file
JCJiarui Cui
Jiarui Cui
JIAMING ZHANGJIAMING ZHANG
JIAMING ZHANG
Cartilage oligomeric matrix protein (COMP) is an extracellular matrix (ECM) glycoprotein that is critical for collagen assembly and ECM stability. Mutations of COMP cause endoplasmic reticulum stress and chondrocyte apoptosis, resulting in rare skeleton diseases. The bouquet-like structure of COMP allows it to act as a bridging molecule that regulates cellular phenotype and function. COMP is able to interact with many other ECM components and binds directly to a variety of cellular receptors and growth factors. The roles of COMP in other skeleton diseases, such as osteoarthritis, have been implied. As a well-established biochemical marker, COMP indicates cartilage turnover associated with destruction. Recent exciting achievements indicate its involvement in other diseases, such as malignancy, cardiovascular diseases, and tissue fibrosis. Here, we review the basic concepts of COMP and summarize its novel functions in the regulation of signaling events. These findings renew our understanding that COMP has a notable function in cell behavior and disease progression as a signaling regulator. Interestingly, COMP shows distinct functions in different diseases. Targeting COMP in malignancy may withdraw its beneficial effects on the vascular system and induce or aggravate cardiovascular diseases. COMP supplementation is a promising treatment for OA and aortic aneurysms while it may induce tissue fibrosis or cancer metastasis.

5 February 2018 in Cell Proliferation
Verified
Journal Article
Closed access
PDF file
JIAMING ZHANGJIAMING ZHANG
JIAMING ZHANG
MYMinuo Yin
Minuo Yin
GPGang Peng
Gang Peng
YZYingchao Zhao
Yingchao Zhao